Abstract：
UNASSIGNED: Osteoporosis is a chronic systemic skeletal disorder characterized by compromised bone strength and an increased risk of fracture, with a high prevalence worldwide. It is associated with a negative quality of life and an increased morbidity and mortality. Postmenopausal women are more prone to develop osteoporosis, and many of them will suffer at least one fragility fracture along their lifetime.
UNASSIGNED: This review starts by summarizing the pathogenesis of postmenopausal osteoporosis (PMO), with focus on the estrogen deficiency-associated bone loss. It continues with the current PMO diagnostic and fracture risk prediction tools, and it finally addresses management of PMO. All the efficacy and safety profiles of the current and future osteoporosis medications are reviewed. Furthermore, strategies to optimize the long-term disease management are discussed. For this review, only publications in English language were selected. References were extracted from PubMed, Embase, and Medline.
UNASSIGNED: PMO disease management is far from being ideal. Educational and communication programs with the goal of improving disease knowledge and awareness, as well as reducing the health-care gap, should be implemented. In addition, most effective sequential prevention and treatment strategies should be initiated from the early menopause.
UNASSIGNED: This review starts by summarizing the pathogenesis of postmenopausal osteoporosis (PMO), with focus on the estrogen deficiency-associated bone loss. It continues with the current PMO diagnostic and fracture risk prediction tools, and it finally addresses management of PMO. All the efficacy and safety profiles of the current and future osteoporosis medications are reviewed. Furthermore, strategies to optimize the long-term disease management are discussed. For this review, only publications in English language were selected. References were extracted from PubMed, Embase, and Medline.
UNASSIGNED: PMO disease management is far from being ideal. Educational and communication programs with the goal of improving disease knowledge and awareness, as well as reducing the health-care gap, should be implemented. In addition, most effective sequential prevention and treatment strategies should be initiated from the early menopause.
摘要：
■骨质疏松症是一种慢性系统性骨骼疾病，其特征是骨强度受损和骨折风险增加。在世界范围内患病率很高。它与负面的生活质量以及增加的发病率和死亡率有关。绝经后妇女更容易发生骨质疏松,他们中的许多人一生中至少会遭受一次脆性骨折。
■本综述从总结绝经后骨质疏松症(PMO)的发病机制入手,重点关注雌激素缺乏相关的骨丢失。它继续使用当前的PMO诊断和断裂风险预测工具，它最终解决了PMO的管理。回顾了当前和未来骨质疏松症药物的所有疗效和安全性。此外，讨论了优化长期疾病管理的策略。对于这篇评论，只选择了英文出版物。参考文献是从PubMed中提取的，Embase和Medline。
■PMO疾病管理远非理想。以提高疾病知识和意识为目标的教育和交流计划，以及缩小医疗保健差距，应该执行。此外,最有效的序贯预防和治疗策略应从绝经早期开始.
■本综述从总结绝经后骨质疏松症(PMO)的发病机制入手,重点关注雌激素缺乏相关的骨丢失。它继续使用当前的PMO诊断和断裂风险预测工具，它最终解决了PMO的管理。回顾了当前和未来骨质疏松症药物的所有疗效和安全性。此外，讨论了优化长期疾病管理的策略。对于这篇评论，只选择了英文出版物。参考文献是从PubMed中提取的，Embase和Medline。
■PMO疾病管理远非理想。以提高疾病知识和意识为目标的教育和交流计划，以及缩小医疗保健差距，应该执行。此外,最有效的序贯预防和治疗策略应从绝经早期开始.
